Uropathy Treatment Market Size & Share 2024 – 2032

Uropathy Treatment Market Size

Uropathy Treatment Market size was valued at USD 4.7 billion in 2023 and is estimated to grow at 4.1% CAGR from 2024 and 2032. The market is expected to experience considerable growth due to the increasing incidence of urinary tract disorders such as urinary tract infections (UTIs), kidney stones, benign prostatic hyperplasia (BPH), and other urological conditions.

According to the National Institutes of Health (NIH), symptoms of urinary retention occur up to 1% to 2% of men with BPH per year. This has contributed to the growing demand for uropathy treatment, as urinary retention is a significant complication of BPH. Thus, widespread adoption uropathy treatment will spur the market growth.
 

Uropathy, also known as obstructive uropathy, a treatment refers to the comprehensive management and care aimed at treating and alleviating disorders affecting the urinary tract obstructive disorder. This includes conditions such as UTIs, kidney stones, BPH, urethral strictures, urinary incontinence, and other urological disorders.
 

Uropathy Treatment Market Trends

Uropathy can be caused by various factors including kidney stones, bladder stones, blood clots, and certain types of cancer such as uterine, colon, and cervical cancer. The occurrence of urological problems with the nerves that supply the bladder can also lead to uropathy. These conditions drive the need for effective treatment options, thereby boosting the market growth.
 

• According to a study published in Advances in Urology, kidney stone disease is a growing urological disorder affecting approximately 15% of the global population. It occurs more frequently in men aged 30-60 years, with around 7% of women and 13% of men developing a kidney stone during their lifetime. This rise in incidence surged the demand for kidney stone management which will increase the demand for treatment options.
   

Therefore, the rising incidence of urological disorders, cancer, combined with technological advancements in drainage procedures and innovations in urinary retention treatments such as extracorporeal shock wave lithotripsy, are the primary factors driving the growth of the market.
 

Uropathy Treatment Market Analysis

Based on treatment type, the market is categorized into medication, drainage devices, surgical procedures, and other treatments. The drainage devices segment is poised to lead the market, with projections to reach a value of USD 2.9 billion by the end of 2032. The drainage devices are further bifurcated into catheters and ureteral stents.
 

• The segment's prominence is fueled by their effectiveness in providing immediate relief and preventing complications, making them a preferred choice in clinical settings.
   
• Also, the growing advancement in drainage devices aimed to improve functionality, safety, and patient comfort, contributing to their widespread adoption and further bolstering the dominance of the segment in the market.
   
• For instance, in May 2022, Lee Ponsky, MD, along with Dean Secrest, received FDA 510k clearance for their newly invented Relief Stent. This approval aimed to expand the marketing of the stent in the U.S., offering relief to patients with kidney stones and related kidney drainage complications. The introduction of the stent aimed to introduce a new drainage device to ease urinary flow addressing the complications of urinary retention.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on age group, the uropathy treatment market is classified into below 20, 21 – 40, 41 - 60, and 61 - 80. The 41-60 years age group segment holds the largest market share of 51.1% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• The high segmental share is due to the increased prevalence of urological conditions such as kidney stones and urinary tract infections in the 41-60 age group. This is attributable to lifestyle choices, dietary habits, and age-related changes in kidney function.
   
• Additionally, advancements in medical imaging techniques for diagnosis and treatment planning will surge the demand for effective treatment, thereby fueling the market growth.
   

Based on the end-user, the uropathy treatment market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and other end-users. The hospitals segment accounted for the largest revenue share in the market expected to account for USD 1.8 billion by 2032.
 

• The hospital boasts specialized urology departments furnished with advanced technologies and staffed by skilled multidisciplinary teams. Their expertise extends to treating various urological disorders such as kidney stones, urinary tract infections, and prostate issues. Also, their leading position is the result of their strong research capabilities, access to state-of-the-art diagnostics and treatments, and a track record of delivering exceptional care and positive patient results.
   
• Such aforementioned benefits associated with hospital setting will foster the market growth.
   

U.S. dominated the North American uropathy treatment market accounting for USD 1.9 billion in 2023 and is anticipated to show significant growth over the analysis period.

• The increasing prevalence of urological disorders, including a rising occurrence of urinary retention within the population, is driving demand for effective treatments for obstructive uropathy in the country.
   
• For instance, as reported by the American Academy of Family Physicians (AAFP), kidney stones are a prevalent condition, with an annual incidence of 8 cases per 1,000 adults. Similarly, the overall incidence of urinary retention ranges from 4.5 to 6.8 cases per 1,000 men annually in the U.S. alone. This surge in condition will emphasis more on effective treatment options, thereby augmenting the country level market expansion.
   

Germany exhibited a high growth potential in the European uropathy treatment market.
 

• Germany holds a prominent position in the European market, leveraging its advanced healthcare infrastructure with the growing emphasis on advanced technologies and innovative treatment approaches to address urological disorders.
   
• The market is witnessing significant advancements in minimally invasive surgeries, robotic-assisted procedures, and personalized medicine strategies. These developments aimed to enhance patient outcomes, improve treatment efficacy, and ensure rapid recovery times.
   

The Asia Pacific uropathy treatment market is poised for rapid growth with a CAGR of 4.5% during the forecast period.
 

• The Asia-Pacific region is poised for significant growth due to the increasing prevalence of urological disorders, coupled with the region's expanding aging population. Also, rising healthcare expenditure and government initiatives aimed at enhancing urological healthcare services are further stimulating market growth.
   
• Furthermore, growing public health campaigns and educational initiatives pertaining to urological diseases will promote for early detection, and personalized treatment plans, thereby driving the market growth.
   

Uropathy Treatment Market Share

The market is characterized by the presence of several prominent players and a diverse range of products and services. Major companies operating in this market include pharmaceutical manufacturers, medical device companies, and service providers. These companies compete on various fronts such as product innovation, pricing strategies, geographical expansion, and strategic collaborations. Additionally, partnerships with healthcare facilities and academic institutions for research and development further contribute to market competitiveness.
 

Uropathy Treatment Market Companies

Some of the prominent players operating in the uropathy treatment industry include:

• Astellas Pharma Inc.
• B. Braun Melsungen AG
• Becton, Dickinson, and Company
• Boston Scientific Corporation
• Cook Medical
• Glaxo SmithKline Pharmaceuticals Ltd.
• Inceler Medikal Co. Ltd.
• KARL STORZ
• Purdue Pharma
• Olympus America
• Pfizer Inc.
• Sun Pharmaceutical Industries Europe B.V.
• Synthon BV
• Teleflex Incorporated.
• UROMED Kurt Drews KG
   

Uropathy Treatment Industry News:

• In April 2024, Ingenion Medical Ltd. received a CE mark for its Cymactive 2.0R urinary catheter, intended for men dealing with chronic, non-neurogenic urinary retention. This approval is expected to expand its outreach to untapped economies.
   
• In November 2021, The Flume Catheter Company (TFCC) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its indwelling urinary catheter. This strategy enabled company to enhance their product offerings.
   

The uropathy treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medication
  • Antibiotics
  • Alpha-blockers or alpha-reductase inhibitors
  • Other medications
• Drainage devices
  • Catheters
    • Indwelling catheters
    • Intermittent catheter
    • Suprapubic catheter
  • Ureteral stents
• Surgical procedure
• Other treatment types

Market, By Age Group

• Below 20
• 21 - 40
• 41 - 60 
• 61 - 80

Market, By End-user

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa